

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listing of claims in the application:

**Listing of claims:**

Claims 1 to 4 (Cancelled).

| Claim 5. (Currently amended) The method of claim 14, wherein said administration is selected from the group consisting of: intravenous, oral, intranasal, subcutaneous, topical and intraperitoneal administration.

Claim 6 to 13. (Previously cancelled)

| Claim 14 (Currently amended) A method for the treatment of gout in a human individual suffering therefrom, comprising administering intravenously or -subcutaneously to said human a therapeutically effective amount of an antibody directed against S100A8 protein in combination with an antibody directed against S100A9 protein, wherein said therapeutically effective amount is sufficient to inhibit the migration of neutrophils involved in the pathogenesis of gout.